In: Nursing
come up with 5 topics on a current literature review of the drug Glatiramer(copaxone)
And provide 6 primary literature references for each topic
Drug Glatiramer (copaxone) current literature reviews:
1. Glatiramer Acetate 40 mg/mL in Relapsing–Remitting Multiple Sclerosis (2015)
2. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis (2015)
3. Spasticity in multiple sclerosis and role of glatiramer acetate treatment (2015)
4. Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic (2014)
5. Pharmacogenomics of interferon beta and glatiramer acetate response (2014)
6. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis (2013)
7. Glatiramer Acetate in the Treatment of Multiple Sclerosis (2011)
References:
Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev. 2013;12(5):543–53.
Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol. 2008;255(Suppl 1):26–36.
Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs. 2010;70(12):1545–77.
Comi G, Cohen JA, Arnold DL, et al. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011;69(1):75–82.
Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis. Ann Neurol. 2013;73(6):705–13.
Lalive PH, Neuhaus O, Benkhoucha M, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011;25(5):401–14.
Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs. 2002;16(12):825–50.